Skip to main content

Advertisement

SpringerLink
Log in

ALZHEIMER’S DISEASE

A needle for Alzheimer’s in a haystack of claims data

  • News & Views
  • Published:

From Nature Aging

View current issue Submit your manuscript

An Author Correction to this article was published on 11 January 2022

This article has been updated

In the era of big data, looking for insights in large datasets has become the norm — and health data are no exception. Combining systems-biology-driven, endophenotype-based analysis of drug targets with large-scale medical claims data points to sildenafil as a potential treatment opportunity for Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Endophenotype-based drug prioritization and population-based validation for drug repurposing in Alzheimer’s disease.

Change history

References

  1. Fang, J. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00138-z (2021).

  2. Uthayathas, S. et al. Pharmacol. Rep. PR 59, 150–163 (2007).

    CAS  PubMed  Google Scholar 

  3. Sanders, O. J. Alzheimers Dis. Rep. 4, 91–106 (2020).

    Article  Google Scholar 

  4. Gottesman, I. I. & Gould, T. D. Am. J. Psychiatry 160, 636–645 (2003).

    Article  Google Scholar 

  5. Guney, E., Menche, J., Vidal, M. & Barábasi, A.-L. Nat. Commun. 7, 10331 (2016).

    Article  CAS  Google Scholar 

  6. Ghiassian, S. D. et al. Sci. Rep. 6, 27414 (2016).

    Article  CAS  Google Scholar 

  7. Menche, J. et al. Science 347, 1257601 (2015).

    Article  Google Scholar 

  8. Aguirre-Plans, J. et al. Pharmaceuticals 11, 61 (2018).

    Article  CAS  Google Scholar 

  9. Cheng, F. et al. Nat. Commun. 9, 2691 (2018).

    Article  Google Scholar 

  10. Langhauser, F. et al. NPJ Syst. Biol. Appl. 4, 8 (2018).

    Article  Google Scholar 

  11. Aguirre-Plans, J. et al. J. Mol. Biol. 431, 2477–2484 (2019).

    Article  CAS  Google Scholar 

  12. Cirillo, D. et al. NPJ Digit. Med. 3, 81 (2020).

    Article  Google Scholar 

  13. Bearden, C. E. & Freimer, N. B. Trends Genet. 22, 306–313 (2006).

    Article  CAS  Google Scholar 

  14. Geifman, N., Kennedy, R. E., Schneider, L. S., Buchan, I. & Brinton, R. D. Alzheimers Res. Ther. 10, 4 (2018).

    Article  Google Scholar 

  15. Götz, J., Matamales, M., Götz, N. N., Ittner, L. M. & Eckert, A. Front. Physiol. 3, 320 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), Barcelona, Spain

    Emre Guney

  2. Discovery and Data Science (DDS) Unit, STALICLA R&D SL, Barcelona, Spain

    Emre Guney

  3. Accenture, Barcelona, Spain

    Alejandro Athie

Authors
  1. Emre Guney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandro Athie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emre Guney.

Ethics declarations

Competing interests

E.G. is an employee of STALICLA, a clinical-stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders through endophenotyping and artificial intelligence. A.A. is an employee of Accenture.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guney, E., Athie, A. A needle for Alzheimer’s in a haystack of claims data. Nat Aging 1, 1083–1085 (2021). https://doi.org/10.1038/s43587-021-00139-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-021-00139-y

  • Springer Nature America, Inc.

Search

Navigation